Department of Radiation Oncology, University Hospital Münster, 48149, Münster, Germany.
Department of Gynecology and Obstetrics, University Hospital Münster, 48149, Münster, Germany.
J Cancer Res Clin Oncol. 2021 Nov;147(11):3299-3312. doi: 10.1007/s00432-021-03743-y. Epub 2021 Jul 22.
While the stem cell marker Musashi-1 (MSI-1) has been identified as a key player in a wide array of malignancies, few findings exist on its prognostic relevance and relevance for cancer cell death and therapy resistance in breast cancer.
First, we determined prognostic relevance of MSI-1 in database analyses regarding multiple survival outcomes. To substantiate findings, MSI-1 was artificially downregulated in MCF-7 breast cancer cells and implications for cancer stem cell markers, cell apoptosis and apoptosis regulator p21, proliferation and radiation response were analyzed via flow cytometry and colony formation. Radiation-induced p21 expression changes were investigated using a dataset containing patient samples obtained before and after irradiation and own in vitro experiments.
MSI-1 is a negative prognostic marker for disease-free and distant metastasis-free survival in breast cancer and tends to negatively influence overall survival. MSI-1 knockdown downregulated stem cell gene expression and proliferation, but increased p21 levels and apoptosis. Similar to the MSI-1 knockdown effect, p21 expression was strongly increased after irradiation and was expressed at even higher levels in MSI-1 knockdown cells after irradiation. Finally, combined use of MSI-1 silencing and irradiation reduced cancer cell survival.
MSI-1 is a prognostic marker in breast cancer. MSI-1 silencing downregulates proliferation while increasing apoptosis. The anti-proliferation mediator p21 was upregulated independently after both MSI-1 knockdown and irradiation and even more after both treatments combined, suggesting synergistic potential. Radio-sensitization effects after combining radiation and MSI-1 knockdown underline the potential of MSI-1 as a therapeutic target.
尽管干细胞标志物 Musashi-1(MSI-1)已被确定为广泛恶性肿瘤的关键因素,但关于其预后相关性以及对乳腺癌细胞死亡和治疗耐药性的相关性的研究发现甚少。
首先,我们在针对多种生存结局的数据库分析中确定了 MSI-1 的预后相关性。为了证实研究结果,我们在 MCF-7 乳腺癌细胞中人工下调了 MSI-1,并通过流式细胞术和集落形成分析,分析了对癌症干细胞标志物、细胞凋亡和凋亡调节因子 p21、增殖和辐射反应的影响。使用包含患者在照射前后获得的样本的数据集以及我们的体外实验来研究辐射诱导的 p21 表达变化。
MSI-1 是乳腺癌无病和无远处转移生存的负预后标志物,并且倾向于对总生存产生负面影响。MSI-1 敲低下调了干细胞基因表达和增殖,但增加了 p21 水平和凋亡。与 MSI-1 敲低效应相似,照射后 p21 表达强烈增加,并且在照射后的 MSI-1 敲低细胞中表达水平更高。最后,MSI-1 沉默和照射的联合使用降低了癌细胞的存活率。
MSI-1 是乳腺癌的预后标志物。MSI-1 沉默下调增殖,同时增加凋亡。增殖抑制剂 p21 在 MSI-1 敲低和照射后均独立上调,甚至在两种处理联合后上调更多,提示存在协同作用。联合使用放疗和 MSI-1 沉默后产生的放射增敏作用强调了 MSI-1 作为治疗靶点的潜力。